Both the functional acquired mutation and overexpression of TRPC6 can lead to kidney diseases, such as focal and segmental glomerulosclerosis, fibrosis and renal cell carcinoma (26–29). This evidence concerns the gene TRPC6 and renal cell carcinoma.